Cats and Chemotherapy: Treat as 'small dogs' at your peril

Journal of Feline Medicine and Surgery

Volumn 15, Issue 5, 2013, Pages 419-424

  Kent, Michael Sean ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANIS FAMILIARIS;

EID: 84876450854     PISSN: 1098612X     EISSN: 15322750     Source Type: Journal    
DOI: 10.1177/1098612X13483240     Document Type: Article

References (25)

1. Price GS,Frazier DL.Use of body surface area (BSA)-based dosages to calculate chemotherapeutic drug dose in dogs: I. Potential problems with current BSA formulae.J Vet Intern Med. 1998;12:267-271.
2. Hill RC,Scott KC.Energy requirements and body surface area of cats and dogs.J Am Vet Med Assoc. 2004;225:689-694.
3. Shah SS,Sanda S,Regmi NL,Sasaki K,Shimoda M.Characterization of cytochrome P450-mediated drug metabolism in cats.J Vet Pharmacol Ther. 2007;30:422-428.
4. Shrestha B,Reed JM,Starks PT,Kaufman GE,Goldstone JV,Roelke ME, et al.Evolution of a major drug metabolizing enzyme defect in the domestic cat and other felidae: phylogenetic timing and the role of hypercarnivory.PLoS One. 2011;6:e18046.
5. Stein TJ,Pellin M,Steinberg H,Chun R.Treatment of feline gastrointestinal small-cell lymphoma with chlorambucil and glucocorticoids.J Am Anim Hosp Assoc. 2010;46:413-417.
6. Rassnick KM,Rodriguez CO,Khanna C,Rosenberg MP,Kristal O,Chaffin K, et al.Results of a phase II clinical trial on the use of ifosfamide for treatment of cats with vaccine-associated sarcomas.Am J Vet Res. 2006;67:517-523.
7. Rassnick KM,Moore AS,Northrup NC,Kristal O,Beaulieu BB,Lewis LD, et al.Phase I trial and pharmacokinetic analysis of ifosfamide in cats with sarcomas.Am J Vet Res. 2006;67:510-516.
8. Rassnick KM,Gieger TL,Williams LE,Ruslander DM,Northrup NC,Kristal O, et al.Phase I evaluation of CCNU (lomustine) in tumor-bearing cats.J Vet Intern Med. 2001;15:196-199.
9. Musser ML,Quinn HT,Chretin JD.Low apparent risk of CCNU (lomustine)-associated clinical hepatotoxicity in cats.J Feline Med Surg. 2012;14:871-875.
10. Skorupski KA,Durham AC,Duda L,Sorenmo KU.Pulmonary fibrosis after high cumulative dose nitrosourea chemotherapy in a cat.Vet Comp Oncol. 2008;6:120-125.
11. O'Keefe DA,Sisson DD,Gelberg HB,Schaeffer DJ,Krawiec DR.Systemic toxicity associated with doxorubicin administration in cats.J Vet Intern Med. 1993;7:309-317.
12. Ogilvie GK,Moore AS,Obradovich JE,Elmslie RE,Vail DM,Straw RC, et al.Toxicoses and efficacy associated with administration of mitoxantrone to cats with malignant tumors.J Am Vet Med Assoc. 1993;202:1839-1844.
13. Knapp DW,Richardson RC,DeNicola DB,Long GG,Blevins WE.Cisplatin toxicity in cats.J Vet Intern Med. 1987;1:29-35.
14. Hahn KA,McEntee MF,Daniel GB,Legendre AM,Nolan ML.Hematologic and systemic toxicoses associated with carboplatin administration in cats.Am J Vet Res. 1997;58:677-679.
15. Kisseberth WC,Vail DM,Yaissle J,Jeglum KA,Couto CG,Ward H, et al.Phase I clinical evaluation of carboplatin in tumor-bearing cats: a Veterinary Cooperative Oncology Group study.J Vet Intern Med. 2008;22:83-88.
16. Cho ES,Lowndes HE,Goldstein BD.Neurotoxicology of vincristine in the cat. Morphological study.Arch Toxicol. 1983;52:83-90.
17. LeBlanc AK,Cox SK,Kirk CA,Newman SJ,Bartges JW,Legendre AM.Effects of L-asparaginase on plasma amino acid profiles and tumor burden in cats with lymphoma.J Vet Intern Med. 2007;21:760-763.
18. Graham-Mize CA,Rosser EJ.Bioavailability and activity of prednisone and prednisolone in the feline patient.Vet Dermatol. 2004;15:7-10.
19. London CA.Tyrosine kinase inhibitors in veterinary medicine.Top Companion Anim Med. 2009;24:106-112.
20. European Medicines Agency. Palladia: European Public Assessment Report - Scientific Discussion. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/veterinary/000150/WC500060743.pdf. 2009.
21. Lachowicz JL,Post GS,Brodsky E.A phase I clinical trial evaluating imatinib mesylate (Gleevec) in tumor-bearing cats.J Vet Intern Med. 2005;19:860-864.
22. Isotani M,Yamada O,Lachowicz JL,Tamura K,Yagihara H,Fujino Y, et al.Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours.Br J Haematol. 2010;148:144-153.
23. Backlund B,Cianciolo RE,Cook AK,Clubb FJ,Lees GE.Minimal change glomerulopathy in a cat.J Feline Med Surg. 2011;13:291-295.
24. Bellamy F,Bader T,Moussy A,Hermine O.Pharmacokinetics of masitinib in cats.Vet Res Commun. 2009;33:831-837.
25. Daly M,Sheppard S,Cohen N,Nabity M,Moussy A,Hermine O, et al.Safety of masitinib mesylate in healthy cats.J Vet Intern Med. 2011;25:297-302.